Johnson & Johnson Reports Q3 2022 Results

New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL RESULTS Q3($ in Millions, except EPS)20222021% ChangeReported Sales  $23,791  $23,338  1.9%Net Earnings    $4,458    $3,66721.6%EPS (diluted)      $1.68     $1.37 22.6%     Q3Non-GAAP* ($ in Millions, except EPS)20222021%  ChangeOperational Sales1,2  8.1%Adjusted Operational Sales1,3  8.2%Adjusted Net Earnings1,4           $6,779           $6,968(2.7%)Adjusted EPS (diluted)1,4               $2.55               $2.60(1.9%)  1 Non-GAAP financial measure; refer to...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news